Immuno-oncology

Conference Coverage

Pembrolizumab takes on r/r PMBCL

LUGANO, SWITZERLAND – Keynote 170 investigators are enrolling adults with relapsed/refractory PMBCL who are either ineligible for ASCT following...

Pages